Variable expressed methylation sites of aging-related genes in asthma

Yu Yang  
Central South University Xiangya School of Medicine

Lin Yuan  
Central South University Xiangya School of Medicine

Ming Yang  
University of Newcastle

Xizi Du  
Central South University Xiangya School of Medicine

Ling Qin  
Central South University Xiangya School of Medicine

Leyuan Wang  
Central South University Xiangya School of Medicine

Kai Zhou  
Central South University Xiangya School of Medicine

Mengping Wu  
Central South University Xiangya School of Medicine

Ruoxi He  
Central South University Xiangya School of Medicine

Juntao Feng  
Central South University Xiangya School of Medicine

Yang Xiang  
Central South University Xiangya School of Medicine

Xiangping Qu  
Central South University Xiangya School of Medicine

Huijun Liu  
Central South University Xiangya School of Medicine

Xiaoqun Qin  
Central South University Xiangya School of Medicine

Chi Liu (✉ liu.chi@csu.edu.cn)  
Central South University Xiangya School of Medicine  https://orcid.org/0000-0003-2872-9576

Research

Keywords: Aging-related genes, DNA methylation, Aging, Asthma,

DOI: https://doi.org/10.21203/rs.3.rs-84789/v1
Abstract

**Background:** Asthma is a complex pulmonary inflammatory disease which is common in the elderly. Aging-related alterations have also been found in the structural cells and immune cells of asthma patients although the pathological mechanism of the differential aging-related gene in the development of asthma is still obscure. Of note, DNA methylation (DNAm) have been proven to play an important role in the regulation of aging-related genes. However, the methylation levels of aging-related genes in asthma patients are largely unclear.

**Methods:** First, the mRNA levels and DNAm level of the previous screened 9 aging-related genes in peripheral blood of 51 healthy controls (HCs) and 55 asthmatic patients were detected by multiple targeted bisulfite enrichment sequencing (MethTarget) and qPCR. Secondly, the correlation between the DNAm level of specific altered CpG sites and the pulmonary function indicators of asthma patients was evaluated. Lastly, the Receiver Operator Characteristic (ROC) curve and Principal Component Analysis (PCA) were used to identify the feasibility of the candidate CpG sites as asthma markers.

**Results:** The mRNA expression of the 9 aging-related gene in peripheral blood of asthma patients was significantly different from those of HCs. Besides, the methylation level of the 9 aging-related genes also altered in asthma patients, and a total of 68 CpG sites were related to the severity of asthma. Notably, 10 of the 68 CpG sites had a significant relationship with pulmonary function parameters. Moreover, ROC curve and PCA analysis showed that the candidate differential methylation sites (DMSs) can be used as potential biomarkers for asthma.

**Conclusions:** In summary, this study confirmed the changes in the mRNA expression and DNAm level of aging-related genes in asthma patients. The differential DMSs are associated with the clinical evaluation indicators of asthma, which may indicate the involvement of aging-related genes in the pathogenesis of asthma and provide some new possible biomarker of asthma.

Introduction

Asthma is a complex pulmonary inflammation disease which is characterized by aberrant immune responses to allergen, reversible airflow obstruction, airway hyper-responsiveness (AHR) and other environmental insulants. Although bronchodilators and inhaled/systemic corticosteroids are highly effective in most asthma patients, approximately 5–10% asthma patients are still steroid-refractory which always have lower lung function and higher mortality [1, 2]. Classical "allergic constitution" or "airway inflammation' cannot fully explain the occurrence and development of asthma. Thus, more and more studies are trying to seek novel inner pathogenesis of asthma and identify new possible therapeutic targets.

Intriguingly, asthma is general in the elderly (age over 65 years) which is often more severe, with little opportunities of remission [3]. Accumulative studies have demonstrated the involvement of aging in the parthenogenesis of chronic pulmonary diseases containing idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary diseases (COPD). As is known that the pathological changes in asthma resemble COPD and IPF, such as airway remodeling, chronic inflammation and decreased lung function [4, 5]. It is feasible to speculate the possible involvement of aging in the development of asthma. Indeed, some valuable evidences have implicated that aging is a vital dangerous factor for the development of asthma [6]. Aging-related changes have also been found in the structural cells and immune cells of asthma patients. Of particular note is that the hallmarks of aging such as telomere attrition, epigenetic alterations, loss of proteostasis, and altered intercellular communication have been detected in asthma patients [7]. Besides, aging can influence the severity and presentation of asthma along with its
diagnosis and management which is significant for the treatment of asthma [6]. The aging of different targeted cells can also promote to the pathobiology of asthma, including airway inflammation, airway remodeling and decreased lung function [8]. Furthermore, it has been confirmed that anti-aging strategies can improve pathological processes such as airway inflammation and airway remodeling in asthma patients. [9].

Although more and more undeniable studies have evidenced the association between aging and asthma. It is still obscure about the mechanisms of aging and its precise effect in the development of asthma. A serious of recent researches have demonstrated that epigenetic mechanisms are involved in the regulation of the expression of aging-related gene [10, 11]. Epigenetic mechanisms containing DNAm, microRNAs expression and histone modifications could regulate the transcription activities of target genes without alteration of nucleotide sequence. In particularly, DNAm is the most deeply studied epigenetic regulation, which have been proven to play a crucial role in the regulation of aging-related genes [12]. Specifically, it has been verified that cytosine methylation at the CpG site affected multiple regulatory mechanisms of aging-related genes during transcription [13, 14] and further participated in aging-related disease such as asthma and COPD [15–17]. However, there is still no definitive literature on the DNAm variations of aging-related genes in asthma patients.

Our previous study screened and evaluated the differentially expression and methylation levels of 9 aging-related genes (AREG, ATG3, E2F1, FOXO3, HDAC1, MMP2, NUF2, TGFB1 and TP53) in COPD patients [18]. It is found that DNAm regulates the expression of 9 aging-related genes in peripheral venous blood of COPD patients. Besides, the methylation level of certain special CpG sites was closely related to the incidence and severity of COPD [18]. To further probe the potential involvement of these previous screened 9 aging-related genes in the parthenogenesis of asthma, we aim to probe the involvement of DNAm of aging-related genes in asthma patients. In our study, we firstly inspected the expression and DNAm level of the 9 aging-related genes in peripheral venous blood of HCs and asthmatic patients. Then, we analyzed the correlation between DMSs and clinical indicators in asthmatic patients. Finally, we assessed the feasibility of specific DMSs’ methylation levels or methylation change rates as biomarkers to distinguish asthma from HCs.

**Methods**

**Subjects and data collection**

The study was approved by No. 20180308 of the Xiangya Hospital Ethics Review Committee. From October 2018 to January 2019, 51 HC and 55 asthma patients were chosen from the Respiratory Department and Physical Examination Center of Xiangya Hospital, China. FEV$_1$/FVC ratio < 0.7 and FEV$_1$% <70% was defined as the presence of asthma. The inclusive standards for the patient group were between the age of 40 and 70 with a clear diagnosis of asthma (according to the criteria of 2019 Global Strategy for Asthma Management and Prevention) and no other respiratory and cardiovascular diseases, diabetes [19]. The healthy control group had no differences in age and gender without asthma or other organic mental diseases, including smoking and non-smoking controls. Quality control methods were strictly enforced.

After obtaining the written informed consent from each subject, we collected questionnaire information (general condition, smoking history and other respiratory diseases), pulmonary function testing and peripheral blood samples. For our analysis, pulmonary function parameters were adopted including forced expiratory volume in one second as percentage of predicted volume (FEV$_1$%), the spirometric values of forced expiratory volume in one second (FEV$_1$), forced vital capacity (FVC), peak expiratory force (PEF) and forced expiratory flow (FEF). Certified
staff performed all interviews and examinations. Moreover, feedback on work quality would be regularly provided to field staff during the data collection process, and secondary training would be conducted when necessary.

**Sample Collection**

A total of 106 whole blood samples were collected from the enrolled 51 HCs and 55 asthma patients, respectively. Then, collected peripheral blood was placed into 5 ml EDTA anticoagulation tubes and transferred to a centrifuge tube. After adding 2 volumes of erythrocyte lysate and lysing for 5 minutes, peripheral blood cells were pelleted by centrifugation and stored at -80°C.

**RNA extraction and quantitative RT-PCR**

Total mRNA was purified from peripheral blood cells using Trizol (Invitrogen) and quantified by an ultraviolet spectrophotometer (Thermo Fisher Scientific, USA) [20]. 1 µg RNA was reverse transcribed into cDNA using Reverse Transcriptase Kit (Qiagen, Netherlands) accordance to the manufacturer's instructions [21]. Then, quantitative RT-PCR was executed using SYBR® Premix Ex Taq™ II system (TaKaRa, Japan) with the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, USA). 1 µl of the reverse-transcript was added to a 30 µl PCR mixture for 40 cycles. Each cycle included 93°C for 30 s and 54°C for 60 s. By the comparison between the copy numbers of target gene and β-actin, the normalization of mRNA expression data for sample-to-sample variability in RNA input, RNA quality and reverse transcription efficiency was completed. Primer sequences were described in Table 1.
### Table 1
Primer sequence of aging-related genes for qPCR.

| Gene  | Primer         |
|-------|----------------|
| AREG  | forward TGTCGCTCTTGTGATACCTCGGC |
|       | reverse AGGCATTTCACCTCACTACAGGGG |
| ATG3  | forward GTGTCAGTTACCCCATGCAG |
|       | reverse TTAACAGCCATTGCGCCACTAATCT |
| E2F1  | forward CATCCCAGAGTGGTGACTTCTG |
|       | reverse GACAAACAGCTGTTGCTCTC |
| FOXO3 | forward CGGACA AACGGCTCACTCT |
|       | reverse GGACCAGCATGAATCGACTAT |
| HDAC1 | forward TTTTTGGGTYGGAYGTTGAG |
|       | reverse CCCTCRCACCTGCCTCTCC |
| MMP2  | forward TGGCACCATTACACCTAC |
|       | reverse CCTCGTATACCAGCATCAATC |
| NUF2  | forward TGTTAAGCAATACAAACGCACAG |
|       | reverse TGCCCTTCAATACCGCTCGT |
| TGFβ1 | forward CGACTCAGGAGTGGTTAT |
|       | reverse GCTAAGGCAAGCCCTCAA |
| TP53  | forward AAGTCTGTGACTTGCACGTACTCC |
|       | reverse GTCATGTGCTGTGACTGCTTGTAG |
| β-actin | forward TTCCAGCCTTCTTTCCTGAA |
|       | reverse TTGCAGCTCAGGAGGAGCAAAT |

**DNA Extraction, Bisulfite Treatment, Methylation Array Methods**

A commercially available kit (TIANGEN Biotech, Beijing, China) was used to extract genomic DNA from whole blood according to previous publications [22]. Genesky Biotechnologies Inc. Shanghai performed bisulfite processing, methylation library construction, high-throughput sequencing and quality control [23]. CpG islands located between 2K upstream of the gene transcription start site and 1K downstream of the first exon were selected to measure methylation level. 18 CpG islands from the 9 screened aging-related genes were selected (2 from AREG, 2 from ATG3, 1 from E2F1, 3 from FOXO3, 1 from HDAC1, 3 from MMP2, 1 from NUF2, 3 from TGFβ1 and 2 from TP53) according to our previous publications [18]. Then, bisulfite modification of DNA sample, methylation library construction and MethTarget were performed [18]. 856 CpG sites from 9 differentially expressed aging-related
genes in the methylation assay were detected. We only selected the original data with a sequencing quality value of Q > 40 (basic sequencing error rate < 0.1%), and the methylation percentage of each CpG site was presented.

**Statistical analysis**

The characteristic data of all recruited asthma patients and HCs were showed as Mean ± SD, \( p \)-value < 0.05, analyzed by unpaired T test. T test and nonparametric test (Mann-Whitney U test) were used to analyze the mRNA expression and the methylation array of AREG, ATG3, E2F1, FOXO3, HDAC1, MMP2, NUF2, TGFB1 and TP53. We used the Benjamin Hochberg method to control the false discovery rate (FDR). The selection of distinguishingly expressed CpG sites was performed by Logistic regression analysis, with latent risk factors of age and gender [24]. The correlation between the percentage of methylation of candidate CpG sites and successive variables for instance FEV\(_1\) %, FVC, FEV\(_1\) and PEF was assessed by Pearson’s correlation or Spearman’s correlation. ROC analysis was obtained to elucidate the accuracy of candidate DMSs or methylation change rate s in predicting asthma. For each candidate DMS, the optimal cutoff value for predicting asthma and corresponding sensitivity and specificity were defined by the maximum Youden index value (sensitivity + specificity-1) [25]. The methylation percentage of candidate DMSs or the methylation status (change or not change) were used for PCA to identify asthma. For each candidate DMS, the change in methylation status was defined by its optimal threshold [26]. The methylation change rate in each sample mainly referred to the probability that the methylation status of the candidate DMSs changed. The statistical analyses were implemented using SPSS version 22.0 (IBM Corporation, Armonk, NY, USA). A two-tailed \( p \)-value < 0.05 was considered statistically significant, **** \( p < 0.0001; * p < 0.05.

**Results**

**Differential expression of the 9 screened aging-related genes in peripheral blood of asthma patients**

In order to detect the expression of the previous screened 9 aging-related genes in asthma patients, peripheral blood was collected from 51 HCs and 55 asthma patients, respectively. The demographic characteristics of the all subjects was shown in Table 2. There was no significant difference between in age between asthma patients and HCs. Compared with the control group, the mRNA expression of AREG, ATG3, E2F1, FOXO3, HDAC1, MMP2, NUF2, TGFB1 and TP53 in the asthma group changed significantly (Fig. 1).
Table 2
Demographic characteristics of asthma patients and HCs.

|                          | Control       | Asthma        |
|--------------------------|---------------|---------------|
| Number of subjects       | 51            | 55            |
| Age                      | 53.83 ± 6.84  | 46.72 ± 10.41 |
| Gender (f/m)             | 41/10         | 46/9          |
| FEV$_1$                  | 2.82 ± 0.20   | 1.76 ± 0.62*  |
| FEV$_1$ % predicted       | 0.92 ± 0.25   | 0.70 ± 0.24*  |
| FVC                      | 4.02 ± 0.65   | 2.84 ± 0.85*  |
| FEV$_1$/FVC              | 0.83 ± 0.03   | 0.65 ± 0.16*  |
| PEF                      | 8.34 ± 0.92   | 4.65 ± 0.85*  |
| FEF$_{75}$               | 0.86 ± 0.35   | 0.47 ± 0.22*  |
| FEF$_{50}$               | 0.83 ± 0.34   | 0.37 ± 0.16*  |
| FEF$_{25}$               | 0.72 ± 0.22   | 0.23 ± 0.18*  |

Data are presented as Mean ± SD. *$p$-value < 0.05, asthma patients VS controls (Unpaired t test).

Altered methylation sites in peripheral blood of asthma patients

As the 9 aging-related genes were significantly changed in asthma patients, we further determined the possible regulation of the differential mRNA expression by DNA methylation. We analyzed the total 856 CpG sites in the CpG islands of the 9 aging-related genes. The methylation analysis result was showed via volcano maps (Fig. 2). It is showed that the methylation levels of 68 CpG sites were related to asthma at FDR < 5%. The detailed information of all the differential 68 DMSs were demonstrated in Table S1.

Potential correlation between DMSs in aging-related genes and clinical index of asthma

To further assess whether the differential methylation of the 9 aging-related genes is related to the occurrence and severity of asthma, we detected the correlation between the differential 68 DMSs in aging-related genes and the lung function indicators of asthma patients. The results demonstrated that there were 10 DMSs significantly related to lung function. The maximum correlation coefficient for each DMSs in the correlation analysis was presented in Fig. 3. The remaining correlation analysis data with lung function indicators was showed in Figure S1. For these 10 DMSs, three DMSs (Chr4:75310649, Chr6:108883024, Chr17:7591672) were closely related to at least three clinical indicators. In addition, other three DMSs (Chr4:75310649, Chr20:32274088, Chr6:108882977) were related to two clinical indicators. It has also been shown that the correlation coefficients of the 10 DMSs were all greater than 0.38 with $p$-value < 0.05. It was also particularly noteworthy that Chr17:7591672 was closely related to four lung function indicators (FVC, FEV$_1$, PEF, FEF$_{25}$), with a correlation coefficient of 0.671 and a $p$-value equal to 0.0001. These data strongly suggested that the differential DNAm of the specific aging-related DMS may influence
the occurrence and severity of asthma. The complete data for the 10 DMSs and clinical indicators were showed in Table 3.

| CpG site       | Gene | p-value | FEV1 | FEV1% | FEV1/FVC | PEF | FVC  | FEF75 | FEF50 | FEF25 |
|----------------|------|---------|------|-------|----------|-----|------|-------|-------|-------|
| Chr4:75310649  | AREG | 0.309   | 0.105| 0.093 | 0.33     | 0.933| 0.025| 0.019 | 0.030 |       |
| Chr4:75310649  | AREG | 0.465   | 0.115| 0.135 | 0.512    | 0.687| 0.044| 0.037 | 0.079 |       |
| Chr20:32274088 | E2F1 | 0.035*  | 0.233| 0.223 | 0.022*   | 0.051| 0.05 | 0.05  | 0.068 |       |
| Chr20:32274358 | E2F1 | 0.113   | 0.059| 0.968 | 0.182    | 0.033| 0.306| 0.543 | 0.641 |       |
| Chr6:108883024 | FOXO3| 0.044*  | 0.032*| 0.063 | 0.038*   | 0.238| 0.758| 0.195 | 0.05  |       |
| Chr6:108882977 | FOXO3| 0.063   | 0.011*| 0.055 | 0.048*   | 0.366| 0.949| 0.147 | 0.051 |       |
| Chr16:55514392 | MMP2 | 0.064   | 0.243| 0.424 | 0.104    | 0.036| 0.932| 0.365 | 0.223 |       |
| Chr16:55514437 | MMP2 | 0.151   | 0.198| 0.75  | 0.102    | 0.025| 0.343| 0.489 | 0.246 |       |
| Chr1:163291825 | NUF2 | 0.508   | 0.038*| 0.157 | 0.202    | 0.793| 0.106| 0.278 | 0.366 |       |
| Chr17:7591672  | TP53 | 0.001*  | 0.113| 0.575 | 0.004*   | 0.000| 0.758| 0.171 | 0.019 |       |

A *p-value < 0.05 was considered statistically significant.

Feasibility of candidate DMSs as biomarkers of asthma

Since the differential 10 DMSs have been confirmed to be closely associated to the clinical parameters of asthma patients, we further evaluated their potential as biomarkers for asthma patients. First, ROC analysis of the methylation levels of each candidate DMS was performed. The areas under the curve (AUC) of 9 DMSs (p-value < 5%) were between 65.3% and 76.3%, and the AUC of 6 DMSs was greater than 70% (Fig. 4A and Table 4). Besides, logistic regression was conducted and the ROC of 9 candidate DMSs showed that the AUC of the predicted probability of the 9 candidate DMSs was as high as 95.4%, and the result was statistically significantly (p-value < 0.1%, Fig. 4B). These results indicated that the 9 candidate DMSs had the potential value for the diagnose of asthma. Meanwhile, to verify the above results, PCA analysis consisting of 9 candidate DMSs was executed. The result revealed that the methylation levels of the total 9 DMSs could effectively distinguish asthma patients from HCs (Fig. 4C).
Table 4
The top 10 differentially methylated sites of the differential aging-related genes associated with asthma.

| CpG site       | Gene | AUC  | p-value  | Optimal diagnostic threshold | Sensitivity | Specificity |
|----------------|------|------|----------|------------------------------|-------------|-------------|
| Chr4:75310649  | AREG | 0.716| 0.009*   | 0.086                        | 0.724       | 0.81        |
| Chr4:75310649  | AREG | 0.691| 0.022*   | 0.019                        | 0.724       | 0.762       |
| Chr20:32274088 | E2F1 | 0.717| 0.009*   | 0.009                        | 0.517       | 0.857       |
| Chr20:32274358 | E2F1 | 0.746| 0.022*   | 0.043                        | 1           | 0.533       |
| Chr6:108883024 | FOXO3| 0.653| 0.066    | 0.166                        | 0.909       | 0.667       |
| Chr6:108882977 | FOXO3| 0.671| 0.040*   | 0.263                        | 0.69        | 0.714       |
| Chr16:55514392 | MMP2 | 0.763| 0.038*   | 0.038                        | 0.69        | 0.614       |
| Chr16:55514437 | MMP2 | 0.688| 0.024*   | 0.017                        | 0.414       | 1           |
| Chr1:163291825 | NUF2 | 0.708| 0.010*   | 0.012                        | 0.862       | 0.571       |
| Chr17:7591672  | TP53 | 0.721| 0.008*   | 0.015                        | 0.966       | 0.476       |

Statistics were done by spss 22.0, A P-value < 0.05 was considered statistically significant.

To better understand the possible value of the 9 DMSs to distinguish asthma, we further calculate the methylation change rate of the 9 DMSs in HCs and asthma patients, which is a description of the possibility of methylation status alteration. Then, the status of the changed methylation or unchanged methylation was determined using the optimal cutoff value. The optimal cutoffs of the 9 DMSs were calculated according to the Youden index which was presented in Table 3. The methylation change rate of HCs and asthmatic patients were included in Fig. 5. Specially, the methylation change rate of the total 9 DMSs in HCs showed a significant decreasing trend, whereas significantly increased methylation change rate was tested in asthma patients (Fig. 5A). The methylation change rate of the total 9 DMSs in asthma was 33.3% ~ 100%, and the rate in HCs was only 0 ~ 55.6%. Notably, the change rate of a single DMS in asthma patients was between 47.27% and 89.09%, while it was 1.96% ~ 41.17% in HCs (Fig. 5B). Similarly, asthma patients had a higher rate of methylation change. Statistical results also showed that the methylation change rate of the total 9 DMSs was significantly increased in asthma patients (p-value < 0.1%, Fig. 6A). In addition, ROC analysis was implemented according to the methylation change rate of the 9 DMSs in all samples (Fig. 6B) and there was a higher AUC compared to previous method (AUC = 0.98). Moreover, the PCA analysis results also indicated that the methylation change rate of 9 DMSs could better distinguish asthma patients from HCs effectively (Fig. 6C).

Discussion

Asthma is a common chronic pulmonary disease, and its prevalence has been increased over the past few decades [27]. With the increase in morbidity, more interventions and novel tactics are urgently needed for asthma patients to further reduce admission and fatality. Of particular note is the potential role of aging in the parthenogenesis of asthma [28, 29]. Many studies have demonstrated the exist of aging structural cells, immune cells and mesenchymal cells in asthmatic lung although the specific role of aging cells in asthma is still not fully understood [20, 30, 31]. Meanwhile, some related studies have also confirmed the different expression of aging-related genes (such as TP53 and FOXO3) in the development of respiratory diseases [32, 33]. The polymorphism of transcription factor FOXO3 has been shown to be involved in the overactivation of mast cells, down-regulation of anti-
inflammatory factors and production of cytokines during the pathogenesis of COPD and asthma [34]. FOXO3 deficiency shows a new role in regulating lung inflammation of COPD/emphysema, which has become a new way to promote the development of pulmonary inflammatory diseases [35]. Similarly, TP53 has been shown to be involved in the progression of COPD by mediating the senescence of multiple lung cells [36]. It has also shown that TP53 is overexpressed in emphysema tissues, which can promote the progression of emphysema in COPD patients [33].

Not only that, as a stable epigenetic marker, DNAm has attracted increasing attention for its involvement in aging-related diseases [37–39]. Aging-related CpG sites have insufficient DNAm or DNA hypermethylation in COPD and other aging-related diseases [40, 41]. Our previous research identified the differential expression and DNAm level of aging-related genes in COPD patients [18]. As asthma and COPD have similar even overlapping clinical phenotypes in chronic inflammation and decreased lung function. In our study, we further explored the methylation change of the previous screened aging-related genes in peripheral venous blood of asthma patients. Indeed, the involvement of these screened 9 aging-related genes in asthma have been extensively studied by previous literatures [42–49].

AREG, E2F1, FOXO3, HDAC1, MMP2, TGFB1 and TP53 have been verified to be the key molecules through different pathways in asthma [32, 50–56]. Although ATG3 is a key molecule that inducing autophagy damage during aging [57], and NUF2 is a gene closely related to aging of lung cells [58], their specific role in asthma has rarely been studied. The differential expression of ATG3, FOXO3, NUF2 and TP53 in asthma patients were also aligned with former studies [32, 58–60]. In addition, excessive secretion of AREG in the airway after an acute attack of asthma promote airway remodeling [56]. However, the downregulated expression of AREG is present in peripheral blood of elderly asthma patients, which may be due to the discrepancy in different disease processes. It is particularly worth noting that the decreased expression of E2F1 in asthma patients is consistent with what we have previously observed in COPD patients [18]. However, it is different from the expression of E2F1 in the lung tissue of lung cancer patients [60]. One possible reason is the specificity of the sample tissue and pathogenic genes. MMP2, as a member of the matrix metalloproteinase family, has an upward trend in the acute and chronic stages of lung disease. Our results observed the increased expression of MMP2 in asthma patients which is also similar to previous literatures [61].

Additionally, we tested the methylation status of the 9 aging-related genes in asthma patients. The methylation level in most DMS of asthma patients were up-regulated, which was consistent with the differential expression of mRNA, indicating that DNAm may be related to the expression of aging-related genes. Moreover, except for ATG3, HDAC1, and TGFB1, correlation analysis showed that the expression of the aging-related genes in peripheral blood of asthma patients was significantly correlated with pulmonary function parameters (FEV1, FEV1/FVC, PEF, FEF75, FEF50, FEF25). It is known that TGFB1 was a key regulatory cytokine in the process of airway remodeling [62] and HDAC1 played a vital role in the pathogenesis of asthma [63]. This partial difference may be due to the single nucleotide polymorphism in asthma [64]. Chr16:55514392 located in the promoter region has a regulatory effect on gene expression, which is obviously negatively correlated with lung function index (FVC) [65]. Interestingly, Chr16:55514437 is also located at the transcription initiation site, but the specific mechanism of its regulatory genes still needs further study [65]. Furthermore, there were 9 asthma-related CpG sites on the CpG islands of the differential aging-related genes. The ROC curve and PCA analysis of methylation level showed that all the 9 DMSs could be used as potential biomarkers to distinguish asthma from HCs. Most notably, the methylation rate of both single DMS and total 9 DMSs in asthma patients were significantly higher than that of HCs. As the difference in population and ethnicity during the disease process may induce the alteration of methylation, we assumed that the methylation variation rate range can better predict the occurrence of asthma. Our analysis of the 9 DMSs methylation mutation rate also produced a better ROC specificity and sensitivity, suggesting that the DMSs had a
great potential to predict asthma from HCs. BALF (IL-25 and IL-33, etc.), induced sputum (eosinophils, Th2 cells, etc.) and airway remodeling (collagen deposition, thickening of basement membrane) could all be used as an useful indicators of asthma diagnosis [66, 67]. However, the detect of DNAm in peripheral blood has greater advantage of widespread access to samples and simple operation. Not only that, DNAm is an important cause of asthma exacerbation, the specific role of allergens and environmental exposure on the epigenetic modification during the development of asthma exacerbation also deserved more attention [68].

Although our study provide potential diagnostic value for asthma assessment, there are also some limitations. Firstly, asthma can be divided into different phenotypes which may have altered epigenetic modification. Besides, our previous work is not comprehensive enough to screen aging-related genes. Moreover, the sample size is relatively small which still need more samples in the future work.

**Conclusions**

In a word, this study demonstrated that DNAm may regulate the differential mRNA expression of aging-related genes in the peripheral blood of asthma patients. Besides, the identified differential DMSs in aging-related genes has an intense correlation with pulmonary function index of asthma patients. These results provide a new clue for the involvement of aging in asthma, which may also offered some potential biomarkers for the early diagnosis of asthma.

**Abbreviations**

DNAm: DNA methylation; ROC: Receiver Operator Characteristic; PCA: Principal Component Analysis; DMSs: differential methylation sites; AHR: airway hyper-responsiveness; IPF: idiopathic pulmonary fibrosis; COPD: chronic obstructive pulmonary diseases; FEV\textsubscript{1}\%: forced expiratory volume in one second as percentage of predicted volume; FEV\textsubscript{1}: the spirometric values of forced expiratory volume in one second; FVC: forced vital capacity; PEF: peak expiratory force; FEF: forced expiratory flow.

**Declarations**

**Ethics approval and consent to participate**

This study was approved by Document No. 20180308 of the Xiangya Hospital Ethics Review Committee. All necessary informed consents in writing were obtained from all patients for permission to use their clinical information and samples for analysis.

**Consent for publication**

Not applicable.

**Availability of data and materials**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.
Funding information

This work was funded by grants #81970033, #31900424, #81670002 and #31671188 from the NSFC; grants #2020JJ4776, #2020JJ4688, #2019JJ50760 from the Hunan Natural Science Foundation; grant #16K097 from open Foundation of Hunan College Innovation Program and grant #2018zzts813, #2018zzts812, #2019zzts327, #2019zzts1008 from the Fundamental Research Funds for the Central Universities of Central South University.

Authors’ contributions

YY: carried out the experiments, analyzed and interpreted the data and drafted the manuscript. YY, YL and WM, YM: collected clinical samples. WL, DX, QL, ZY and WS: performed the experiments and statistical analysis. XY, QX, LH, QX and LC: analyzed and interpreted the data, provided the project funding and revised the manuscript. LC: analyzed and interpreted the data, revised the manuscript and finally approved the version of the manuscript for publication. All authors provided critical feedback and helped shape the research, analysis and manuscript.

Acknowledgments

We appreciate the Key laboratory of Basic and Clinical Respiratory Diseases in Hunan Province for offering the equipment and experiment condition.

References

1. Luhadia, S.K., Steroid resistant asthma. J Assoc Physicians India, 2014. 62(3 Suppl): p. 38-40.
2. Maltby, S., et al., Mouse models of severe asthma: Understanding the mechanisms of steroid resistance, tissue remodelling and disease exacerbation. Respirology, 2017. 22(5): p. 874-885.
3. Dunn, R.M., P.J. Busse, and M.E. Wechsler, Asthma in the elderly and late-onset adult asthma. Allergy, 2018. 73(2): p. 284-294.
4. Aghasafari, P., U. George, and R. Pidaparti, A review of inflammatory mechanism in airway diseases. Inflamm Res, 2019. 68(1): p. 59-74.
5. Zhou-Suckow, Z., et al., Airway mucus, inflammation and remodeling: emerging links in the pathogenesis of chronic lung diseases. Cell Tissue Res, 2017. 367(3): p. 537-550.
6. Budde, J. and G.S. Skloot, Is aging a "comorbidity" of asthma? Pulm Pharmacol Ther, 2018. 52: p. 52-56.
7. Kennedy, B.K., et al., Geroscience: linking aging to chronic disease. Cell, 2014. 159(4): p. 709-713.
8. Wang, Z.N., et al., Potential Role of Cellular Senescence in Asthma. Front Cell Dev Biol, 2020. 8: p. 59.
9. Conte, E., et al., Anti-inflammatory and antifibrotic effects of resveratrol in the lung. Histol Histopathol, 2015. 30(5): p. 523-529.
10. Johnson, A.A., et al., The role of DNA methylation in aging, rejuvenation, and age-related disease. Rejuvenation Res, 2012. 15(5): p. 483-494.
11. Field, A.E., et al., DNA Methylation Clocks in Aging: Categories, Causes, and Consequences. Mol Cell, 2018. 71(6): p. 882-895.
12. Yang, I.V., et al., Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2014. 190(11): p. 1263-1272.
13. Zhu, H., G. Wang, and J. Qian, *Transcription factors as readers and effectors of DNA methylation*. Nat Rev Genet, 2016. **17**(9): p. 551-565.
14. Morales-Nebreda, L., F.S. McLafferty, and B.D. Singer, *DNA methylation as a transcriptional regulator of the immune system*. Transl Res, 2019. **204**: p. 1-18.
15. Nicodemus-Johnson, J., et al., *DNA methylation in lung cells is associated with asthma endotypes and genetic risk*. JCI Insight, 2016. **1**(20): p. e90151.
16. Morrow, J.D., et al., *DNA methylation profiling in human lung tissue identifies genes associated with COPD*. Epigenetics, 2016. **11**(10): p. 730-739.
17. Morrow, J.D., et al., *Human Lung DNA Methylation Quantitative Trait Loci Colocalize with Chronic Obstructive Pulmonary Disease Genome-Wide Association Loci*. Am J Respir Crit Care Med, 2018. **197**(10): p. 1275-1284.
18. Du, X., et al., *Variable DNA methylation of aging-related genes is associated with male COPD*. Respir Res, 2019. **20**(1): p. 243.
19. *Global Strategy for Asthma Management and Prevention*. Available from: https://ginasthma.org/gina-reports/.
20. Yuan, L., et al., *ITGB4 deficiency induces senescence of airway epithelial cells through p53 activation*. Febs J, 2019. **286**(6): p. 1191-1203.
21. Yuan, L., et al., *Airway epithelial integrin β4 suppresses allergic inflammation by decreasing CCL17 production*. Clin Sci (Lond), 2020. **134**(13): p. 1735-1749.
22. Koshy, L., et al., *Evaluating genomic DNA extraction methods from human whole blood using endpoint and real-time PCR assays*. Mol Biol Rep, 2017. **44**(1): p. 97-108.
23. Li, J.J., et al., *Familial Hypercholesterolemia Phenotype in Chinese Patients Undergoing Coronary Angiography*. Arterioscler Thromb Vasc Biol, 2017. **37**(3): p. 570-579.
24. Miravitlles, M., et al., *Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis*. The EOLO Study Group. Respiration, 2000. **67**(5): p. 495-501.
25. Fluss, R., D. Faraggi, and B. Reiser, *Estimation of the Youden Index and its associated cutoff point*. Biom J, 2005. **47**(4): p. 458-472.
26. Saito, H., et al., *Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients*. Yonago Acta Med, 2017. **60**(2): p. 119-125.
27. Mazurek, J.M. and G. Syamlal, *Prevalence of Asthma, Asthma Attacks, and Emergency Department Visits for Asthma Among Working Adults - National Health Interview Survey, 2011-2016*. MMWR Morb Mortal Wkly Rep, 2018. **67**(13): p. 377-386.
28. Vignola, A.M., et al., *Aging and asthma: pathophysiological mechanisms*. Allergy, 2003. **58**(3): p. 165-175.
29. Bullone, M. and J.P. Lavoie, *The Contribution of Oxidative Stress and Inflamm-Aging in Human and Equine Asthma*. Int J Mol Sci, 2017. **18**(12).
30. Goldstein, B.D., et al., *Chronic asthma and Mesenchymal stem cells: Hyaluronan and airway remodeling*. J Inflamm (Lond), 2017. **14**: p. 18.
31. Kim, J., et al., *Innate immune crosstalk in asthmatic airways: Innate lymphoid cells coordinate polarization of lung macrophages*. J Allergy Clin Immunol, 2019. **143**(5): p. 1769-1782.e11.
32. Amarin, J.Z., et al., *An intrinsic single-nucleotide polymorphism (rs13217795) in FOXO3 is associated with asthma and allergic rhinitis: a case-case-control study*. BMC Med Genet, 2017. **18**(1): p. 132.
33. Hu, W.P., et al., *Identification of novel candidate genes involved in the progression of emphysema by bioinformatic methods.* Int J Chron Obstruct Pulmon Dis, 2018. 13: p. 3733-3747.

34. Barkund, S., et al., *FOXO3a Gene Polymorphism Associated with Asthma in Indian Population.* Mol Biol Int, 2015. 2015: p. 638515.

35. Hwang, J.W., et al., *FOXO3 deficiency leads to increased susceptibility to cigarette smoke-induced inflammation, airspace enlargement, and chronic obstructive pulmonary disease.* J Immunol, 2011. 187(2): p. 987-998.

36. Hashimoto, Y., et al., *27-Hydroxycholesterol accelerates cellular senescence in human lung resident cells.* Am J Physiol Lung Cell Mol Physiol, 2016. 310(11): p. L1028-41.

37. Zahiruddin, A.S., J.A. Grant, and S. Sur, *Role of epigenetics and DNA-damage in asthma.* Curr Opin Allergy Clin Immunol, 2018. 18(1): p. 32-37.

38. Salam, M.T., *Asthma epigenetics.* Adv Exp Med Biol, 2014. 795: p. 183-199.

39. Wu, M., et al., *DNA methylation down-regulates integrin β4 expression in asthmatic airway epithelial cells.* Clin Exp Allergy, 2020.

40. Perez, R.F., et al., *Distinct chromatin signatures of DNA hypomethylation in aging and cancer.* Aging Cell, 2018. 17(3): p. e12744.

41. Sundar, I.K., et al., *DNA methylation profiling in peripheral lung tissues of smokers and patients with COPD.* Clin Epigenetics, 2017. 9: p. 38.

42. Xu, Q., et al., *Targeting amphiregulin (AREG) derived from senescent stromal cells diminishes cancer resistance and averts programmed cell death 1 ligand (PD-L1)-mediated immunosuppression.* Aging Cell, 2019. 18(6): p. e13027.

43. Gao, S., et al., *E2F1 mediates the downregulation of POLD1 in replicative senescence.* Cell Mol Life Sci, 2019. 76(14): p. 2833-2850.

44. Martins, R., G.J. Lithgow, and W. Link, *Long live FOXO: unraveling the role of FOXO proteins in aging and longevity.* Aging Cell, 2016. 15(2): p. 196-207.

45. Wu, D. and C. Prives, *Relevance of the p53-MDM2 axis to aging.* Cell Death Differ, 2018. 25(1): p. 169-179.

46. Wang, S., et al., *Ablation of toll-like receptor 4 attenuates aging-induced myocardial remodeling and contractile dysfunction through NCoR1-HDAC1-mediated regulation of autophagy.* J Mol Cell Cardiol, 2018. 119: p. 40-50.

47. de Sousa Neto, I.V., et al., *Effects of Resistance Training on Matrix Metalloproteinase Activity in Skeletal Muscles and Blood Circulation During Aging.* Front Physiol, 2018. 9: p. 190.

48. von Bernhardi, R., L. Eugenin-von Bernhardi, and J. Eugenin, *Microglial cell dysregulation in brain aging and neurodegeneration.* Front Aging Neurosci, 2015. 7: p. 124.

49. Huang, W., et al., *ATG3, a Target of miR-431-5p, Promotes Proliferation and Invasion of Colon Cancer via Promoting Autophagy.* Cancer Manag Res, 2019. 11: p. 10275-10285.

50. Xu, W., *Expression data analysis to identify biomarkers associated with asthma in children.* Int J Genomics, 2014. 2014: p. 165175.

51. Nakagome, K. and M. Nagata, *Pathogenesis of airway inflammation in bronchial asthma.* Auris Nasus Larynx, 2011. 38(5): p. 555-563.

52. Toujani, S., et al., *Role of metalloproteinases MMP-2 in asthma.* Tunis Med, 2016. 94(6): p. 167-171.
53. Hur, G.Y. and D.H. Broide, Genes and Pathways Regulating Decline in Lung Function and Airway Remodeling in Asthma. Allergy Asthma Immunol Res, 2019. 11(5): p. 604-621.

54. Butler, C.A., et al., Glucocorticoid receptor beta and histone deacetylase 1 and 2 expression in the airways of severe asthma. Thorax, 2012. 67(5): p. 392-398.

55. Wang, J., et al., Amphiregulin potentiates airway inflammation and mucus hypersecretion induced by urban particulate matter via the EGFR-PI3Ka-AKT/ERK pathway. Cell Signal, 2019. 53: p. 122-131.

56. Enomoto, Y., et al., Tissue remodeling induced by hypersecreted epidermal growth factor and amphiregulin in the airway after an acute asthma attack. J Allergy Clin Immunol, 2009. 124(5): p. 913-920.

57. Frudd, K., T. Burgoyne, and J.R. Burgoyne, Oxidation of Atg3 and Atg7 mediates inhibition of autophagy. Nat Commun, 2018. 9(1): p. 95.

58. Xing, Y., et al., Identification of hub genes of pneumocyte senescence induced by thoracic irradiation using weighted gene coexpression network analysis. Mol Med Rep, 2016. 13(1): p. 107-116.

59. Xuan, L.L. and Q. Hou, [Recent advances in the study of AMPK and inflammatory pulmonary disease]. Yao Xue Xue Bao, 2014. 49(8): p. 1089-1096.

60. Tsai, M.J., et al., Deducting MicroRNA-Mediated Changes Common in Bronchial Epithelial Cells of Asthma and Chronic Obstructive Pulmonary Disease-A Next-Generation Sequencing-Guided Bioinformatic Approach. Int J Mol Sci, 2019. 20(3).

61. Greenlee, K.J., Z. Werb, and F. Kheradmand, Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev, 2007. 87(1): p. 69-98.

62. Dragicevic, S., N. Petrovic-Stanojevic, and A. Nikolic, TGFB1 Gene Promoter Polymorphisms in Serbian Asthmatics. Adv Clin Exp Med, 2016. 25(2): p. 273-278.

63. Wang, C., et al., Identification of differentially expressed genes associated with asthma in children based on the bioanalysis of the regulatory network. Mol Med Rep, 2018. 18(2): p. 2153-2163.

64. Shan, L., et al., Effects of Single-Nucleotide Polymorphisms in the TLR7 and TLR9 Genes of Asthmatic Children. Ann Clin Lab Sci, 2018. 48(5): p. 601-607.

65. Haberle, V. and A. Stark, Eukaryotic core promoters and the functional basis of transcription initiation. Nat Rev Mol Cell Biol, 2018. 19(10): p. 621-637.

66. Lefaudeux, D., et al., U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol, 2017. 139(6): p. 1797-1807.

67. Li, Y., et al., Elevated Expression of IL-33 and TSLP in the Airways of Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease. J Immunol, 2018. 200(7): p. 2253-2262.

68. Bae, D.J., et al., Epigenetic Changes in Asthma: Role of DNA CpG Methylation. Tuberc Respir Dis (Seoul), 2020. 83(1): p. 1-13.

Figures
Figure 1

The mRNA levels of aging-related genes in HCs and asthma patients. (A-I) The mRNA expression of AREG, ATG3, E2F1, FOXO3, HDAC1, MMP2, NUF2, TGFB1, and TP53 in HCs and asthma patients. **** p < 0.0001.
Figure 2

Volcano plot of the differential methylation CpG sites between HCs and asthma patients. The up-regulated sites were presented as green dots and down-regulated were presented as red dots. *p<0.05 sites were presented above the dotted line.
Figure 3

The correlation between differential methylation sites and clinical parameters of asthma patients. (A-B) The methylation level of Chr4:75310649 and Chr4:75310649 were positively correlated with FEF50. (C) The methylation level of Chr20:32274088 was positively correlated with PEF. (D-G) The methylation level of Chr20:32274358, Chr16:55514392, Chr16:55514437 and Chr17:7591672 were positively correlated with FVC. (H-J) The methylation levels of Chr6:108883024, Chr1:163291825 and Chr6:108882977 was negative correlated with FEV1%.

Figure 4

The accuracy of the methylation level of the 9 DMSs in predicting asthma. (A) ROC curve analysis of differential CpG sites Chr4:75310649, Chr4:75310649, Chr20:32274088, Chr20:32274358, Chr6:108882977, Chr16:55514392, Chr16:55514437, Chr1:163291825 and Chr17:7591672, respectively. (B) The ROC curve of the predicted probability of the 9 DMSs. (C) A PCA plot consisting of the methylation levels of the 9 DMSs in HCs and asthma patients.

Figure 5
Methylation change rate for asthma patients. (A) The methylation change rate of the 9 DMSs in asthma patients and HCs is represented by pie chart, and the dark shades indicates the percentage of the methylation change rate. (B) Difference in methylation rate of single DMS in HCs and asthma patients.

Figure 6

The accuracy of the 9 DMSs’ methylation change rate in predicting asthma. (A) Statistical analysis of the methylation change rate of the 9 DMSs in HCs and asthma patients. (B) ROC curve analysis of the methylation change rate in the 9 DMSs. (C) A PCA plot consisting of methylation change rate of the 9 DMSs in HCs and asthma patients.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- OnlineFigureS1.png
- TableS1.docx